Grand Pharmaceutical Group Ltd
HKEX:512
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.28
5.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Grand Pharmaceutical Group Ltd
Total Liabilities & Equity
Grand Pharmaceutical Group Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Total Liabilities & Equity
HK$24.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Total Liabilities & Equity
HK$12.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Total Liabilities & Equity
¥22.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Total Liabilities & Equity
¥66.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
20%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Total Liabilities & Equity
HK$266.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Total Liabilities & Equity
$1.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
19%
|
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The firm is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
See Also
What is Grand Pharmaceutical Group Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
24.9B
HKD
Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Total Liabilities & Equity amounts to 24.9B HKD.
What is Grand Pharmaceutical Group Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
18%
Over the last year, the Total Liabilities & Equity growth was 11%. The average annual Total Liabilities & Equity growth rates for Grand Pharmaceutical Group Ltd have been 10% over the past three years , 13% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
